WHAT IS LCGC

							      LCGC DBD2 Model                                Why?
  Accelerated path for target        Drug leads for new biological targets
                                                                                Double-Blinded
  validation and prioritization
  requiring far lower commitment
                                     lie latent in Pharma compound
                                     collections that the DBD2 model can
                                                                                Drug Discovery
                                                                                        2™
  of internal resources.             repurpose. The model was designed
                                     to measurably enhance ROI from
                                                                                    DBD
  Enhance monetization of non-       underperforming      chemical     assets
  performing chemical assets.        representing billions of investment
                                     dollars. LCGC offers a new impact
  Innovative approach for de-        opportunity for biology and chemistry
  risking and then exclusively in-   Therapeutic Area Heads to fortify and
  licensing novel and promising      diversify collaborative networks and
  drug targets.                      enhance scientific enablement with low
                                     budgetary impact. The model is
  Public-Private Partnering (PPP)    consistent with the desire in academia
  under a totally new and timely     for better enablement in leads discovery
  licensing model.                   and the need in Pharma to lower R&D
                                     costs.        DBD2 allows deferring
  Transparent. Milestone-gated.      internal resource deployment on
  IP secure. Acceptable risk.        immature projects that siphon limited
                                     core resources, which can adversely
  Ready for engagement.              impact pipeline projects.


    Contact Information                              How?
                                     Compound libraries from pharma are
    Melvin Reichman, Ph.D.           made available for target validation and
      President and CSO              lead finding in academia in a new way
LIMR Chemical Genomics Center        with 500% improved efficiency. When
   100 E. Lancaster Avenue           potent, efficacious and selective leads
    Wynnewood, PA 19096              are found, the provider may execute an
     Phone: 484.476.8230             exclusive licensing option, or sponsor
                                     additional research to further develop
 E-mail: ReichmanM@mlhs.org          technology with exclusive commercial
                                     applications. All IP remains always
     www.lcgcinc.com                 secure.
Mission: LCGC is a catalyst to                                                   We provide novel assay ready,
enable more effective Public -                                                   orthogonally-pooled screening plates
Private Partnerships in drug                                                     to allow 500% more efficient new
discovery far earlier in the                                                     leads discovery. Along with ensuring
pharmaceutical R&D continuum                                                     assay validity, far more efficient lead
than traditional models allow.                                                   prioritization, and IP security, our
                                                                                 approach       may   detect     hidden
                                                                                 mechanisms of novel drug action in a
                                                                                 radical new way.


                                       LCGC has put in place an innovative,
                                       high-capacity storage and distribution
                                       center for public and private chemical
                                       collections. A unique business model
                                       enables       successful      licensing
                                       outcomes to occur more efficiently.
                                       Importantly, the IP of all parties is
                                       totally protected, while allowing
We offer public and private            joint research to proceed.
segments a totally new licensing                                                 Our specific aim is to accelerate
avenue to far more productively                                                  the     productive   transfer    of
leverage the chemical assets of                                                  technology     with    the    most
pharmas towards the most promising                                               promising medicinal applications
cell-signaling     pathways    under                                             from academia to pharmaceutical
investigation at universities.                                                   companies at a cost and benefit-to-
                                                                                 risk ratio satisfactory to all
                                                                                 participants.




                                       In addition to our proprietary
                                       infrastructure, LCGC offers a unique
                                       drug-like HTS collection that is
                                       unavailable elsewhere.